Literature DB >> 18337056

Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis.

Wei Zhao, Rong Xue, Zhen-Xian Zhou, Wei-Jia Kong, Jian-Dong Jiang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18337056     DOI： 10.1016/j.biopha.2008.01.007

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN： 0753-3322            Impact factor:   6.529


× No keyword cloud information.
  12 in total

Review 1.  Berberine and its derivatives represent as the promising therapeutic agents for inflammatory disorders.

Authors:  Qiukai Lu; Yifan Fu; Heng Li
Journal:  Pharmacol Rep       Date:  2022-01-27       Impact factor: 3.024

2.  Berberine chloride suppresses non-small cell lung cancer by deregulating Sin3A/TOP2B pathway in vitro and in vivo.

Authors:  Jian Chen; Xiaofei Huang; Cheng Tao; Li Wang; Zide Chen; Xinping Li; Qiang Zeng; Min Ma; Ren Zhang; Zhengzhi Wu
Journal:  Cancer Chemother Pharmacol       Date:  2020-06-30       Impact factor: 3.333

3.  Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes.

Authors:  Yi Li; Gang Ren; Yan-Xiang Wang; Wei-Jia Kong; Peng Yang; Yue-Ming Wang; Ying-Hong Li; Hong Yi; Zhuo-Rong Li; Dan-Qing Song; Jian-Dong Jiang
Journal:  J Transl Med       Date:  2011-05-15       Impact factor: 5.531

4.  Berberine Attenuates Development of the Hepatic Gluconeogenesis and Lipid Metabolism Disorder in Type 2 Diabetic Mice and in Palmitate-Incubated HepG2 Cells through Suppression of the HNF-4α miR122 Pathway.

Authors:  Shengnan Wei; Ming Zhang; Yang Yu; Xiaoxin Lan; Fan Yao; Xin Yan; Li Chen; Grant M Hatch
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

Review 5.  A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome.

Authors:  Jamshid Tabeshpour; Mohsen Imenshahidi; Hossein Hosseinzadeh
Journal:  Iran J Basic Med Sci       Date:  2017-05       Impact factor: 2.699

Review 6.  Barberry in the treatment of obesity and metabolic syndrome: possible mechanisms of action.

Authors:  Safieh Firouzi; Mahsa Malekahmadi; Majid Ghayour-Mobarhan; Gordon Ferns; Hamid Reza Rahimi
Journal:  Diabetes Metab Syndr Obes       Date:  2018-11-08       Impact factor: 3.168

7.  Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases.

Authors:  Hui-Hui Guo; Chen-Lin Feng; Wen-Xuan Zhang; Zhi-Gang Luo; Hong-Juan Zhang; Ting-Ting Zhang; Chen Ma; Yun Zhan; Rui Li; Song Wu; Zeper Abliz; Cong Li; Xiao-Lin Li; Xiao-Lei Ma; Lu-Lu Wang; Wen-Sheng Zheng; Yan-Xing Han; Jian-Dong Jiang
Journal:  Nat Commun       Date:  2019-04-30       Impact factor: 14.919

8.  A comparative study on the hepatoprotective action of bear bile and Coptidis Rhizoma aqueous extract on experimental liver fibrosis in rats.

Authors:  Ning Wang; Yibin Feng; Fan Cheung; Oi-Yee Chow; Xuanbin Wang; Weiwei Su; Yao Tong
Journal:  BMC Complement Altern Med       Date:  2012-11-29       Impact factor: 3.659

9.  Berberine Inhibition of Fibrogenesis in a Rat Model of Liver Fibrosis and in Hepatic Stellate Cells.

Authors:  Ning Wang; Qihe Xu; Hor Yue Tan; Ming Hong; Sha Li; Man-Fung Yuen; Yibin Feng
Journal:  Evid Based Complement Alternat Med       Date:  2016-04-30       Impact factor: 2.629

Review 10.  Application of Herbal Medicines with Bitter Flavor and Cold Property on Treating Diabetes Mellitus.

Authors:  Hongdong Chen; Jing Guo; Bing Pang; Linhua Zhao; Xiaolin Tong
Journal:  Evid Based Complement Alternat Med       Date:  2015-10-18       Impact factor: 2.629
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.